A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 [dalcetrapib] mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL [high-density lipoprotein] Levels

Trial Profile

A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 [dalcetrapib] mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL [high-density lipoprotein] Levels

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2008

At a glance

  • Drugs Dalcetrapib; Simvastatin
  • Indications Lipid metabolism disorders
  • Focus Therapeutic Use
  • Sponsors Akros Pharma
  • Most Recent Events

    • 23 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top